Dr. Abhishek Tripathi, MD

Dr. Tripathi practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Tripathi's NPI, 1568750032, was assigned on July 18, 2011. Dr. Tripathi graduated from Maulana Azad Medical College in 2009. Dr. Tripathi holds California license C181620.

Dr. Tripathi's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Tripathi's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Tripathi to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tripathi practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Tripathi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Tripathi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Tripathi's licenses on file in 3 states: California, Oklahoma and Massachusetts.

Dmand AI lists chronic anemia and prostate cancer among the conditions Dr. Tripathi treats.

CMS data shows 1,305 Medicare services from Dr. Tripathi across 5 procedure codes in 2024, for 275 Medicare patients. Medicare paid $94,310 for them.

CMS counts 275 Medicare patients who saw Dr. Tripathi in 2024. The largest group is 65 to 74, with 119 patients. 75% of them have cancer, and 75% have high blood pressure. 26% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tripathi's median patient age at 73, with 10% women.

In 2024, Dr. Tripathi wrote 756 Medicare Part D claims for 124 patients. 51% of them were for generic drugs. CMS names the drug for 613 of them, across 12 drugs with 11 or more claims each, at $2,847,265 in total drug cost. In 2023, CMS named 406 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Tripathi for performance year 2024, reported as part of a group. Dr. Tripathi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tripathi as offering telehealth.

Dmand AI links 83 papers to Dr. Tripathi, published from 2007 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Carcinoma, Transitional Cell, Urinary Bladder Neoplasms and Kidney Neoplasms. Dr. Tripathi has published most often in Clin Genitourin Cancer. Dr. Tripathi's most frequent co-authors are Mehmet Asim Bilen, MD, Tanya B. Dorff, MD and Rana Ramzi McKay, MD.

Dmand AI links Dr. Tripathi to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Ureteral Neoplasms, Urethral Neoplasms and Carcinoma, Transitional Cell. University of Oklahoma sponsors the most, 2. Open Payments lists research payments to Dr. Tripathi that name 1 trial.

CMS Open Payments shows 99 general payments to Dr. Tripathi from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Exelixis Inc. paid the most, $11,882. It also lists 1 research payment totaling $99 in 2018, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Tripathi, most recently Chief Fellow in 2017.

Dr. Tripathi graduated from Maulana Azad Medical College in 2009. Dr. Tripathi is a member of ASCO.

Dr. Tripathi is in network with 13 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.